A5002764596- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- COVID-19 Clinical Research Studies
- Pharmaceutical Practices and Patient Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Potassium and Related Disorders
- Radiomics and Machine Learning in Medical Imaging
- Mechanical Circulatory Support Devices
- Cardiac Arrhythmias and Treatments
- Cardiac Structural Anomalies and Repair
- Cancer, Lipids, and Metabolism
- Helicobacter pylori-related gastroenterology studies
- Pharmaceutical studies and practices
- Sports injuries and prevention
- Transplantation: Methods and Outcomes
- Cardiac Valve Diseases and Treatments
- Digital Imaging in Medicine
- Colorectal Cancer Screening and Detection
- COVID-19 and healthcare impacts
- Thyroid Disorders and Treatments
- Esophageal Cancer Research and Treatment
- Lipoproteins and Cardiovascular Health
- Antimicrobial Resistance in Staphylococcus
University of California, Davis
2023-2024
UC Davis Health System
2024
University of California, Los Angeles
2020-2023
University of Washington
2023
University of California Davis Medical Center
2023
Ronald Reagan UCLA Medical Center
2020-2022
Keck Hospital of USC
2022
VA Greater Los Angeles Healthcare System
2021
Olive View-UCLA Medical Center
2021
UCLA Medical Center
2020
Abstract SARS-CoV-2 infection is associated with significant lung and cardiac morbidity but there a limited understanding of the endocrine manifestations coronavirus disease 2019 (COVID-19). Although thyrotoxicosis due to subacute thyroiditis has been reported in COVID-19, it unknown whether can also lead decompensated hypothyroidism. We present first case myxedema coma (MC) COVID-19 we discuss how may have precipitated multiorgan damage sudden arrest our patient. A 69-year-old woman history...
The STRONG-HF trial (Safety, Tolerability and Efficacy of Up-Titration Guideline-Directed Medical Therapies for Acute Heart Failure) demonstrated substantial reductions in the composite mortality morbidity over 6 months among hospitalized patients with heart failure (HF) who were randomized to intensive guideline-directed medical therapy (GDMT) optimization compared usual care. Whether an GDMT program would be cost-effective HF reduced ejection fraction is unknown.
Three medications are now guideline-recommended treatments for heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), however, the cost-effectiveness of these agents in combination has yet to be established. The purpose this study was determine mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium glucose co-transporter 2 (SGLT2is) individuals HFmrEF/HFpEF. Using a 3-state Markov model, we performed using...
Management of heart failure with reduced ejection fraction (HFrEF) requires timely initiation and up-titration guideline-directed medical therapy (GDMT). In safety-net hospitals (SNHs), limited health care staff resources make achievement optimal challenging. Recent studies have shown that medication titration performed by clinical pharmacists can improve outcomes in ambulatory management HFrEF; however, the impact these services within an SNH remains unknown.Determine integrating into a...
BACKGROUND:The management of fungal endocarditis is difficult due to high mortality and incidence embolization. Fungal blood cultures are the criterion standard for diagnosis but show slow growth or remain negative in more than 50% cases. We present a case which 1,3-β-D-glucan (BG) assay was used initiate antifungal treatment prior culture. CASE REPORT:A 45-year-old man with known intravenous drug use presented Emergency Department acute hypoxemic respiratory failure prominent aortic...
BACKGROUND:Cardiac allograft vasculopathy (CAV) is a post-orthotopic heart transplant (OHT) complication driven by intimal smooth muscle proliferation and immune hyperactivity to donor tissue. Accelerated CAV leads failure within 1 year after receiving normal angiogram result. Viruses can contribute development, but SARS-CoV-2 infection has not been reported date. CASE REPORT:A 48-year-old man, 5 years OHT for non-ischemic cardiomyopathy, was admitted the Cardiac Care Unit with 3 days of...
Ultrasound has now become part of the curriculum for trainees in obstetrics and gynecology UK. is a very commonly performed by trained trainee doctors but also sonographers specialist nursing staff. Previous papers Houston et al (2011) Akhtar have highlighted deficiencies knowledge safety aspects ultrasound. There lack such data from We conducted this survey to ascertain awareness ultrasound amongst sonographers, medical staff who access perform examinations early pregnancy during after...
Introduction: The 2022 American College of Cardiology/American Heart Association (ACC/AHA) guidelines established angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 as Class I therapies in heart failure with reduced ejection fraction (HFrEF). Previous analyses have demonstrated the cost-effectiveness these drugs, but use different methodologies limit comparison. objective this study was to a singular model compare agents HFrEF. Methods: A 2-state Markov developed...
Secondary mitral regurgitation (MR) in patients with heart failure reduced ejection fraction (HFrEF) portends a poor prognosis when it occurs.1 Left ventricular dilation leads to annular of the annulus and coaptation valve leaflets leading secondary MR. Until recently, medical cardiac resynchronization therapy was primary treatment strategy for symptomatic MR, surgical repair reserved select most often undergoing concomitant open surgery. The recent American College Cardiology/American Heart...
OPINION article Front. Cardiovasc. Med., 12 June 2023Sec. Heart Failure and Transplantation Volume 10 - 2023 | https://doi.org/10.3389/fcvm.2023.1193226
Background For patients with heart failure reduced ejection fraction (HFrEF), suboptimal initiation and titration of guideline-directed medical therapy (GDMT) has resulted in preventable loss life function. The STRONG-HF trial reinforced this finding by demonstrating substantial reductions the composite mortality morbidity over 6 months among hospitalized (HF) who were randomized to intensive GDMT optimization compared usual care. Research Question Whether an program would be cost-effective...
Background: In a pooled analysis of the PARAGON-HF and PARAGLIDE-HF trials, sacubitril-valsartan was effective in treatment heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) patients who experienced recent worsening event. Research Question: The cost-effectiveness this patient population has yet to be established. Aim: We performed HFmrEF/HFpEF Methods: Using 2-state Markov model, we simulated vs. placebo populations 1,000 Clinical event rates were based on...